Clinical Trial

Β-OHB Supplementation and Brain Health in Older Adults

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The goal of this randomized placebo controlled crossover trial is investigate the effects of short-term ketone monoester (KME) supplementation to brain function in older adults with subjective cognitive decline. We will test the hypothesis that KME supplementation will increase cerebral blood flow and improve resting-state functional connectivity in the brain compared to placebo supplementation in older adults with subjective cognitive decline. Participants will be randomly assigned to either placebo of KME supplementation for 14 days. Following a washout period, participants will complete the alternate condition for 14 days. Outcome measures will be assessed before and after each intervention period.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-09-05.
Trial Details
NCT Number NCT06588946
Lead Sponsor McMaster University
Collaborators: Heart and Stroke Foundation of Canada
Conditions Subjective Cognitive Decline
Enrollment 48 participants
Start Date 2025-03
Primary Completion 2027-08 (estimated)
Study Completion 2027-08 (estimated)
Updated on ClinicalTrials.gov 2025-02-26